Donate For Public and Patients Store Search

S002 - Vitiligo

Friday, March 1; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize a variety of presentations of vitiligo in both children and adults, and their implications for prognosis and treatment
  • Describe current therapies, their relative efficacy, and limitations
  • Discuss emerging treatments in the context of disease pathogenesis

Description

Recent discoveries in the pathogenesis, risk factors, and features of disease activity have influenced the way that we diagnose and manage vitiligo patients. Clinical trials for vitiligo are ongoing, and new treatments are on the horizon. Patterns of depigmentation in children and adults will be discussed, as well as their differential diagnoses and implications for prognosis and treatment. Current approaches to management and their comparative efficacy will be outlined, and emerging targeted therapies will be characterized. The goal is to empower attendees to approach vitiligo in a way that will lead to improved outcomes for their patients.

Disclosures

  • Desai, Seemal R., MD: AbbVie – I(Grants/Research Funding); Almirall – C(Fees), SP(H); Cassiopea SpA – C(H); Dermavant Sciences – A(Fees); Dermira – C(H), I(Grants/Research Funding), SP(H); Dr. Reddy – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Scientis – C(H), SP(H); SkinCeuticals LLC – C(H);
  • Elbuluk, Nada, MD: no financial relationships exist with commercial interests.
  • Ezzedine, Khaled, MD: no financial relationships exist with commercial interests.
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(NC); Incyte Corporation – I(Grants/Research Funding); Laseroptek USA – I(Grants/Research Funding); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Dermavant Sciences – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); EMD Serono – C(H); Genzyme Corporation – C(H), I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Leo Pharma Inc – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Rheos Medicines – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); TeVido Biodevices, LLC – A(SO), I(Grants/Research Funding), SH(ST); Third Rock Ventures – A(H); Villaris Therapeutics, Inc – F(ST), I(Grants/Research Funding);
  • Midgett, Terrell: no financial relationships exist with commercial interests.
  • Pandya, Amit G., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Clarify Medical Inc. – B(ST); Incyte Corporation – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
  • Passeron, Thierry, MD, PhD: AbbVie – A(H), Speaker/Faculty Education(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Beiersdorf, Inc. – SP(H); Bioderma – Speaker/Faculty Education(H); Celgene Corporation – I(Grants/Research Funding); Galderma Research & Development, LLC – A(H); GlaxoSmithKline – Speaker/Faculty Education(H); ISDIN – A(H), SP(H); Janssen-Cilag – A(H), Speaker/Faculty Education(H); Journal of the European Academy of Dermatology and Venereology – O(NC); L'OrĂ©al Research and Innovation – Speaker/Faculty Education(H); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H); Lancome – C(H); Leo Pharma Inc. – Speaker/Faculty Education(H); Lilly ICOS LLC – Speaker/Faculty Education(H); MSD – A(H); Novartis – A(H), SP(H); Pfizer Inc. – A(H); Sanofi – A(H); Symrise – A(H); Syneron Candela – Speaker/Faculty Education(H);
  • Rodrigues, Michelle, MBBS: Cynosure, Inc. – A(NC); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H);
Schedule
Friday, March 1
9:00 AM
Dr. Harris / Introduction
9:15 AM
Ezzedine / Common, uncommon, and rare presentations of vitiligo
9:30 AM
Dr. Rodrigues / Vitiligo workup and differential diagnosis
9:45 AM
Dr. Desai / Chemicals that induce vitiligo: hazard and treatment
10:00 AM
Dr. Elbuluk / Diet and supplements for vitiligo
10:15 AM
Ezzedine, Dr. Rodrigues, Dr. Desai, and Dr. Elbuluk / Questions
10:30 AM
Passeron / Medical therapy for vitiligo
10:45 AM
Dr. Pandya / Phototherapy for vitiligo
11:00 AM
Dr. Hamzavi / Surgical therapy for vitiligo
11:15 AM
Dr. Grimes / Special considerations in children with vitiligo
11:30 AM
Dr. Harris / Emerging vitiligo treatments
11:45 AM
Dr. Harris, Passeron, Dr. Pandya, Dr. Hamzavi, and Dr. Grimes / Questions
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 12:00 PM
  • Location
    Ballroom A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
Speakers